
Exelixis (EXEL) Stock Forecast & Price Target
Exelixis (EXEL) Analyst Ratings
Bulls say
Exelixis Inc. is poised for a positive outlook primarily due to the strong market positioning of its lead compound, cabozantinib, which continues to demonstrate effectiveness as a leading tyrosine kinase inhibitor (TKI) in renal cell carcinoma (RCC) through long-term data from the CHECKMATE-9ER trial. The company has also expanded the label for cabozantinib, offering new opportunities in neuroendocrine tumors (NETs), indicating potential for revenue growth and market penetration. Furthermore, ongoing successes in indications such as hepatocellular carcinoma (HCC) and management's optimism about continued improvements in treatment outcomes enhance the overall attractiveness of Exelixis’s portfolio.
Bears say
Exelixis Inc faces significant financial challenges, particularly due to an anticipated 80% drop in revenues by 2032 as a result of the impending patent cliff, which analysts believe the market has not fully accounted for. Key risks that contribute to this negative outlook include potential erosion of market share for cabozantinib in renal cell carcinoma and the lack of traction in neuroendocrine tumors, alongside disappointing clinical data for the pipeline drug zanzalintinib. Furthermore, the likelihood of generic competition further compounds these risks, suggesting that the company may struggle to maintain its revenue streams in the coming years.
This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.
Exelixis (EXEL) Analyst Forecast & Price Prediction
Start investing in Exelixis (EXEL)
Order type
Buy in
Order amount
Est. shares
0 shares